Altimmune, Inc. (ALT) Financial Statements
Altimmune, Inc. (ALT) reported trailing twelve-month revenue of $41000 (up 105.0% year on year) and net income of -$91.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$76.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALTAltimmune, Inc.Follow ALT — free
—
Price chart with a free account
- Market cap
- 412.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2021 Dec 21 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.3 | 10.7 | 10.3 | 5.8 | 4.4 | 0.4 | 0.0 | 0.0 | — | |
| Gross profit | — | — | — | 4.8 | — | — | — | — | — | |
| Research & development | 21.2 | 18.4 | 18.5 | 17.8 | 74.5 | 65.8 | 82.2 | 66.4 | 68.2 | |
| Operating income | -11.7 | -52.0 | -42.8 | -21.5 | -96.9 | -95.9 | -103.2 | -94.5 | -100.2 | |
| Pre-tax income | — | -52.1 | -45.3 | -20.6 | -97.1 | -88.4 | -95.1 | -88.8 | -91.8 | |
| Income tax | — | -5.6 | -6.1 | -0.1 | — | — | — | -0.7 | — | |
| Net income | -3.8 | -46.4 | -39.2 | -20.5 | -97.1 | -88.4 | -95.1 | -88.1 | -91.8 | |
| Diluted EPS ($) | -0.08 | -118.91 | -15.16 | -1.60 | -2.35 | -1.66 | -1.34 | -1.00 | -0.49 | |
| Diluted shares (mn) | — | — | — | — | 41.3 | 53.2 | 71.0 | 88.1 | — |
USD millions · SEC XBRL
Altimmune, Inc. — questions
- What is Altimmune, Inc.'s revenue?
- $41000 over the twelve months to 2026-06-30, up 105.0% year on year, from its 10-Q and 10-K filings.
- What is Altimmune, Inc.'s net income?
- -$91.8M over the twelve months to 2026-06-30.
- What is Altimmune, Inc.'s free cash flow?
- -$76.6M over the twelve months to 2026-06-30.
- What are Altimmune, Inc.'s diluted earnings per share?
- $-0.49 over the twelve months to 2026-06-30.
Every figure on this page comes from Altimmune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.